Contact
searchSearch
HMP Global

Myeloproliferative Neoplasms Topic Center

Industry Insights
News

news


News
TKI-Treated CML Survivors Face Long-Term Health and Functional Challenges
08/24/2026
Grace Taylor, MS, MA
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase...
08/24/2026
First Report Managed Care
News
Recent CML Advances Reshape Frontline Treatment and TKI Sequencing
08/19/2026
Hannah Musick
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic...
08/19/2026
First Report Managed Care
News
Later-Generation CML Therapies May Have Limited Effect on Patient Out-of-Pocket Costs
08/12/2026
Hannah Musick
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests...
08/12/2026
First Report Managed Care
News
TKI Dose De-Escalation Preserves Treatment-Free Remission in CML, Study Finds
07/20/2026
Grace Taylor, MS, MA
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine...
07/20/2026
First Report Managed Care
News
Cavhanza Approved by the FDA to Treat Adults With Ph+ CML
07/20/2026
Rebecca Amrick
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been...
07/20/2026
First Report Managed Care
News
Review Finds Low Bleeding Risk With Tyrosine Kinase Inhibitor–Anticoagulant Combinations in CML
07/16/2026
Hannah Musick
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that...
07/16/2026
First Report Managed Care
News
TKI Discontinuation Supports Long-Term Treatment-Free Remission in Chronic-Phase CML
07/08/2026
Grace Taylor, MS, MA
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies...
07/08/2026
First Report Managed Care
News
Food Restrictions May Affect Adherence in Chronic Myeloid Leukemia
06/18/2026
Hannah Musick
Food restrictions associated with certain chronic myeloid leukemia therapies were linked to greater treatment burden, missed doses, and adherence challenges, with more than half of surveyed patients expressing interest in a treatment option...
Food restrictions associated with certain chronic myeloid leukemia therapies were linked to greater treatment burden, missed doses, and adherence challenges, with more than half of surveyed patients expressing interest in a treatment option...
Food restrictions associated...
06/18/2026
First Report Managed Care
News
Food-Restricted TKIs Associated With Adherence Challenges in CML
06/08/2026
Grace Taylor, MS, MA
A US survey of patients with chronic myeloid leukemia (CML) found that food restrictions associated with certain tyrosine kinase inhibitors (TKIs) may complicate daily routines, reduce treatment adherence, and increase interest in more...
A US survey of patients with chronic myeloid leukemia (CML) found that food restrictions associated with certain tyrosine kinase inhibitors (TKIs) may complicate daily routines, reduce treatment adherence, and increase interest in more...
A US survey of patients with...
06/08/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use